Indication
Anemia in beta thalassemia
Anemia in beta thalassemia is an inherited hematologic condition characterized by impaired oxygen-carrying capacity due to deficient or absent synthesis of the beta-globin chains of adult hemoglobin. Read more about Anemia in beta thalassemia
5 drugs 5 manufacturers
Drugs that treat it
Common Anemia in beta thalassemia therapies.
REBLOZYL (luspatercept-aamt)
ZYNTEGLO (betibeglogene autotemcel)
CASGEVY (exagamglogene autotemcel)
AQVESME (mitapivat sulfate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAnemia in beta thalassemia is an inherited hematologic condition characterized by impaired oxygen-carrying capacity due to deficient or absent synthesis of the beta-globin chains of adult hemoglobin.
Primarily affecting individuals of Mediterranean, Middle Eastern, Central and South Asian, and African ancestry, this quantitative hemoglobinopathy results in an excess of unbound alpha-globin chains that form unstable aggregates within developing and mature erythrocytes.
These intracellular precipitates drive hallmark pathophysiologic processes, including premature erythroid precursor destruction within the bone marrow—termed ineffective erythropoiesis—and peripheral hemolysis.
Consequently, patients develop microcytic, hypochromic anemia ranging clinically from mild, asymptomatic presentations to severe, life-threatening transfusion-dependent disease complicated by extramedullary hematopoiesis, splenomegaly, and systemic iron overload.
- nih.gov
Anemia in beta thalassemia is an inherited hematologic condition characterized by impaired oxygen-carrying capacity due to deficient or absent synthesis of the beta-globin chains of adult hemoglobin Primarily affecting individuals of Mediterranean, Middle Eastern, Central and South Asian, and African ancestry, this quantitative hemoglobinopathy results in an excess of unbound alpha-globin chains that form unstable aggregates within developing and mature erythrocytes Consequently, patients develo...
- nih.gov
Anemia in beta thalassemia is an inherited hematologic condition characterized by impaired oxygen-carrying capacity due to deficient or absent synthesis of the beta-globin chains of adult hemoglobin Primarily affecting individuals of Mediterranean, Middle Eastern, Central and South Asian, and African ancestry, this quantitative hemoglobinopathy results in an excess of unbound alpha-globin chains that form unstable aggregates within developing and mature erythrocytes These intracellular precipita...
- nih.gov
Anemia in beta thalassemia is an inherited hematologic condition characterized by impaired oxygen-carrying capacity due to deficient or absent synthesis of the beta-globin chains of adult hemoglobin
- merckmanuals.com
Primarily affecting individuals of Mediterranean, Middle Eastern, Central and South Asian, and African ancestry, this quantitative hemoglobinopathy results in an excess of unbound alpha-globin chains that form unstable aggregates within developing and mature erythrocytes
- nih.gov
These intracellular precipitates drive hallmark pathophysiologic processes, including premature erythroid precursor destruction within the bone marrow—termed ineffective erythropoiesis—and peripheral hemolysis
- nih.gov
Consequently, patients develop microcytic, hypochromic anemia ranging clinically from mild, asymptomatic presentations to severe, life-threatening transfusion-dependent disease complicated by extramedullary hematopoiesis, splenomegaly, and systemic iron overload
Personalize your experience
Follow Anemia in beta thalassemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.